Modeling the Clinical and Economic Burden of Therapeutic Inertia in People with Type 2 Diabetes in Saudi Arabia-Reference-Cited by-同舟云学术

Modeling the Clinical and Economic Burden of Therapeutic Inertia in People with Type 2 Diabetes in Saudi Arabia

Published:2024-09-11 Issue: Volume: Page:
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Alluhidan Mohammed^ORCID,Alturaiki Abdulrahman,Alabdulkarim Hana,Aljehani Nasser,Alghamdi Essam A.,Alsabaan Fahad,Alamri Abdullah A.,Malkin Samuel J. P.,Hunt Barnaby,Alhossan Abdulaziz,Al-Jedai Ahmed

Funder

Novo Nordisk Saudi Arabia

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s12325-024-02978-8.pdf

Reference43 articles.

1. International Diabetes Federation (IDF). Diabetes Atlas – 10th Edition. 2021. Available at: https://diabetesatlas.org/data/en/world/ [Last accessed Oct 19, 2023].

2. Jarrar M, Abusalah MAH, Albaker W, Al-Bsheish M, Alsyouf A, Al-Mugheed K, Issa MR, Alumran A. Prevalence of type 2 diabetes mellitus in the general population of Saudi Arabia, 2000–2020: a systematic review and meta-analysis of observational studies. Saudi J Med Med Sci. 2023;11(1):1–10.

3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.

4. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–89.

5. Stettler C, Allemann S, Jüni P, Cull CA, Holman RR, Egger M, Krähenbühl S, Diem P. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials. Am Heart J. 2006;152(1):27–38.